Head-to-Head Studies for Plaque Psoriasis Therapies

Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.

Related Keywords

Benjamin Lockshin ,Sandy Blauvelt ,Bruce Strober ,Jennifer Soung , ,Plaque Psoriasis ,Head To Studies ,Skin Clearance Rates ,Il 23 Inhibitors ,Meta Analysis ,Acumulative Effect ,Durability ,Risankisumab ,Apremilast ,